WebApr 12, 2024 · Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint WebMar 9, 2024 · As for the Europe Ovarian Cancer Diagnostics and Therapeutics landscape, Germany is projected to reach USD million by 2028 trailing a CAGR of Percent over the forecast period.
Therapeutic Strategies for Recurrent Ovarian Cancer - Medscape
Web2 days ago · Ovarian cancer is one of the most commonly fatal malignant tumors affecting the female genital tract. According to GLOBOCAN 2024 data, around 310,000 new cases … Web2 days ago · About the FLAMES Study. The FLAMES Study is a randomized, double-blind, placebo-controlled, multi-center phase III clinical study to evaluate the efficacy and safety of senaparib as monotherapy maintenance treatment following first-line platinum-based chemotherapy in patients with FIGO stage III/IV ovarian cancer who have achieved … flights newcastle to wagga wagga
The Protein Landscape of Mucinous Ovarian Cancer: Towards a …
WebApr 11, 2024 · Ovarian cancer remains the deadliest among all gynecological cancers. Although most patients at advanced stage respond to initial treatment, the majority experience recurrence [ 1 ]. It was estimated that 55,342 new cases and 37,519 deaths from ovarian cancer occurred in China annually [ 2 ]. WebThe ovarian cancer diagnostics and therapeutics market is projected to register a CAGR of 9.5% during the forecast period. Factors such as increasing ovarian cancer cases across the world and the use of combination therapies for the treatment of ovarian cancer are expected to drive the growth of the market. Web2 days ago · Senaparib was jointly developed by Junshi Biosciences and IMPACT Therapeutics, Inc. (“IMPACT Therapeutics”), as a maintenance treatment following first-line platinum-based chemotherapy in patients with International Federation of Gynecology and Obstetrics (“FIGO”) stage III/IV ovarian carcinoma, fallopian tube cancer or primary … cherry rk